SG11202005510SA - Therapeutic enzyme fusion protein having a novel structure and use thereof - Google Patents

Therapeutic enzyme fusion protein having a novel structure and use thereof

Info

Publication number
SG11202005510SA
SG11202005510SA SG11202005510SA SG11202005510SA SG11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA SG 11202005510S A SG11202005510S A SG 11202005510SA
Authority
SG
Singapore
Prior art keywords
fusion protein
novel structure
enzyme fusion
therapeutic enzyme
therapeutic
Prior art date
Application number
SG11202005510SA
Inventor
Eui Joon Jung
Jin Young Kim
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG11202005510SA publication Critical patent/SG11202005510SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
SG11202005510SA 2017-12-22 2018-12-21 Therapeutic enzyme fusion protein having a novel structure and use thereof SG11202005510SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170178378 2017-12-22
PCT/KR2018/016487 WO2019125059A1 (en) 2017-12-22 2018-12-21 Therapeutic enzyme fusion protein having novel structure and use thereof

Publications (1)

Publication Number Publication Date
SG11202005510SA true SG11202005510SA (en) 2020-07-29

Family

ID=66993643

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005510SA SG11202005510SA (en) 2017-12-22 2018-12-21 Therapeutic enzyme fusion protein having a novel structure and use thereof

Country Status (16)

Country Link
US (1) US20210009984A1 (en)
EP (1) EP3708661A4 (en)
JP (1) JP7403455B2 (en)
KR (2) KR102588611B1 (en)
CN (1) CN111511910A (en)
AR (1) AR113430A1 (en)
AU (1) AU2018388331A1 (en)
BR (1) BR112020012346A2 (en)
CA (1) CA3086474A1 (en)
EA (1) EA202091239A1 (en)
IL (1) IL275248A (en)
MX (1) MX2020006635A (en)
PH (1) PH12020550927A1 (en)
SG (1) SG11202005510SA (en)
TW (1) TW201934753A (en)
WO (1) WO2019125059A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002202A2 (en) * 2019-08-07 2022-06-14 Amicus Therapeutics Inc Methods of treating Fabry disease in patients having a mutation in the gla gene
JP2023545707A (en) 2020-10-14 2023-10-31 デナリ セラピューティクス インコーポレイテッド Fusion protein containing sulfoglucosamine sulfohydrolase enzyme and method thereof
KR20220065720A (en) * 2020-11-13 2022-05-20 한미약품 주식회사 Use of an enzyme fusion protein for prevention or treatment of neuropathy
AU2021378707A1 (en) * 2020-11-13 2023-06-01 Hanmi Pharm. Co., Ltd. Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease
KR20230134823A (en) * 2022-03-15 2023-09-22 주식회사 녹십자 Lyophilized formulation comprising a fusion protein including α-galactosidase A
KR20230134822A (en) * 2022-03-15 2023-09-22 주식회사 녹십자 Liquid Formulation comprising a fusion protein including α-galactosidase A

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215180B (en) 1992-01-23 1998-10-28 Merck Patent Gmbh. Process for production of monomeric and dimeric antibody-fragment fusion proteins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
RU2002110121A (en) * 1999-09-17 2004-03-10 Джитиси Байотерапьютикс, Инк. (Us) Fused Proteins Obtained by Transgenic Method
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
MX2007012457A (en) * 2005-04-11 2007-12-10 Sanofi Pasteur Polymyxin b analogs for lps detoxification.
EA016429B1 (en) 2005-12-30 2012-04-30 Мерк Патент Гмбх Anti-cd19 antibodies with reduced immunogenicity
ES2623925T3 (en) * 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Immunoglobulin Fusion Proteins
WO2015009052A1 (en) * 2013-07-16 2015-01-22 일동제약 주식회사 Fusion protein of immunoglobulin hybrid fc and enzyme
WO2015017548A2 (en) 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
TW201639878A (en) 2014-12-30 2016-11-16 韓美藥品股份有限公司 Glucagon derivatives with improved stability
RU2731202C2 (en) 2015-10-08 2020-08-31 Макродженикс, Инк. Combined therapy for cancer treatment
NZ743008A (en) * 2015-12-08 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
AR107483A1 (en) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd CONJUGATE OF THERAPEUTIC ENZYMES
KR102413686B1 (en) * 2017-07-07 2022-06-28 한미약품 주식회사 Novel therapeutic enzyme fusion protein and use thereof

Also Published As

Publication number Publication date
KR20190076909A (en) 2019-07-02
US20210009984A1 (en) 2021-01-14
KR20230143985A (en) 2023-10-13
KR102588611B1 (en) 2023-10-16
IL275248A (en) 2020-07-30
EP3708661A1 (en) 2020-09-16
AU2018388331A1 (en) 2020-07-02
EA202091239A1 (en) 2020-09-09
MX2020006635A (en) 2020-12-10
WO2019125059A1 (en) 2019-06-27
EP3708661A4 (en) 2021-12-01
CA3086474A1 (en) 2019-06-27
CN111511910A (en) 2020-08-07
AR113430A1 (en) 2020-04-29
JP7403455B2 (en) 2023-12-22
BR112020012346A2 (en) 2020-11-24
PH12020550927A1 (en) 2021-05-10
TW201934753A (en) 2019-09-01
JP2021507705A (en) 2021-02-25

Similar Documents

Publication Publication Date Title
EP3623389A4 (en) Fusion protein containing tgf- receptor and medicinal uses thereof
IL267861A (en) A pd1-41bbl fusion protein and methods of use thereof
IL273439A (en) Fusion proteins comprising enzyme replacement therapy enzymes
IL275248A (en) Therapeutic enzyme fusion protein having a novel structure and use thereof
IL267862A (en) A sirpalpha-41bbl fusion protein and methods of use thereof
IL280102A (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
ZA201900209B (en) Novel natural protein and application thereof
EP3722305A4 (en) Hm-3 fusion protein and use thereof
IL280103A (en) Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
SG11202110400QA (en) Fusion protein and use thereof
SG11202104912SA (en) Fusion protein and use thereof
EP3668551A4 (en) Apom-fc fusion proteins and uses thereof
EP3702362A4 (en) Polypeptide having analgesic activity and use thereof
IL272050A (en) Synthetic proteins and therapeutic uses thereof
IL290660A (en) Therapeutic fusion proteins
EP3816181A4 (en) Improved fviii fusion protein and use thereof
EP3601572A4 (en) Protein expression construct and methods thereof
SG11202111462VA (en) Asx-specific protein ligases and uses thereof
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
HUP1700012A2 (en) Novel proteins and use thereof
IL292599A (en) Tmem219 antibodies and therapeutic uses thereof
EP3875483A4 (en) Fusion protein comprising ids and use thereof
HUE060194T2 (en) Peptide derivatives and therapeutic activity thereof